Vireo Health: Canaccord Reiterates After Q4 Results

Last week, Vireo Health (CSE: VREO) released their fourth quarter and year-end 2020 financial results. The company recorded total GAAP revenue of $12.4 million and $49.2 million, a 38% and 64% increase for the fourth quarter and year-end respectively. Most notably, the company had reported its first quarter of breakeven adjusted EBITDA.

Vireo Health currently has three analysts covering the company with a weighted 12-month price target of C$3.69. One analyst has a strong buy rating, while the others have buy ratings. The street high comes from M Partners with a C$5.25 price target.

Canaccord Genuity reiterated their C$4 price target and speculative buy rating on the company. Matt Bottomley, their analyst, headlines, “Q4/20 review: An in-line print while near-term growth drivers remain somewhat muted.”

Vireo’s quarterly numbers came in slightly below Canaccord’s estimates. The main reason for the slight miss was due to Vireo’s underperformance in their key states of Minnesota and New York. Bottomley writes that the restrictive nature of the medical markets in these states contributed to the low quarter-over-quarter growth. He adds, “we believe VREO still has an attractive long-term growth profile; however, given the somewhat restrictive nature of its core markets, we believe near-term QoQ growth will remain limited.”

Bottomley has lowered their near-term forecasts as they are forecasting a slower revenue acceleration in Minnesota and New York. Below you can see their new estimates.

M Partners meanwhile raised their 12-month price target on Vireo from C$3 to C$5.25 and reiterates their buy rating. Paul Piotrowski, M Partners’ analyst, headlines, “Q4 Results – Outlook Stronger Than Ever With NY Rec Imminent.”

Once more, Vireo’s quarterly numbers came in slightly below their estimates. M Partners forecasted $13.6 million and $5.7 million in revenue and gross profit respectively. Piotrowski writes, “VREO’s NY business is likely to generate upwards of $100M/year in sales and adds at least $270M in EV (or $2/share).”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Cresco Labs: Analysts Raise Targets Following Blowout Quarter

On November 18th, Cresco Labs (CSE: CL) reported their third quarter financial results. The company...

Friday, November 20, 2020, 12:09:00 PM

Canaccord Genuity Initiates Coverage On Artemis Gold With C$13 Price Target

Canaccord Genuity initiated coverage on Artemis Gold (TSXV: ARTG) this morning with a Speculative Buy...

Thursday, September 10, 2020, 03:00:12 PM

Rogers: “Minority Shareholders Need Closure Not Chaos”

Rogers Communications (TSX: RCI) continues to be the centre of attention within the Canadian markets,...

Sunday, October 31, 2021, 04:56:00 PM

Teladoc Health: Numerous Analysts Raise Price Targets Following Q3 Earnings

Yesterday, Teladoc Health (NYSE: TDOC) reported its third quarter earnings results, reporting $228.8 million in...

Saturday, October 31, 2020, 02:02:00 PM

Silvercorp Metals: Canaccord Genuity Initiates Coverage With C$12 Price Target

This morning, Canaccord Genuity’s analyst Dalton Baretto initiated coverage on Silvercorp Metals (TSX: SVM) (NYSE:...

Monday, September 14, 2020, 11:58:00 AM